APRIL inhibition shows promise for treating IgA nephropathy

IgA nephropathy (IgAN) is the most common primary glomerulonephritis globally, leading to chronic kidney disease. Historically, treatment options were limited to supportive care, but new strategies are emerging, including targeting A proliferation-inducing ligand (APRIL) to reduce harmful IgA production. APRIL plays a key role in IgAN by promoting the production of pathogenic IgA1, which causes kidney damage. Inhibiting APRIL could disrupt this process, potentially improving patient outcomes. Several anti-APRIL drugs are currently in clinical trials. Recent advancements in understanding IgAN's pathophysiology have led to more treatment options beyond symptom management. Nephrologists are optimistic about the future of IgAN care as new therapies progress through clinical development.